Oxford scientists probe immune cells to unlock better meningitis protection
NCT ID NCT01593514
First seen May 11, 2026 · Last updated May 19, 2026 · Updated 2 times
Summary
This study examined how different types of meningitis vaccines affect specific immune cells (B cells) in adults aged 30 to 70. Researchers compared older polysaccharide vaccines with newer conjugate vaccines to understand which vaccine triggers a stronger and longer-lasting immune response. The goal is to use this knowledge to design better vaccines that protect all age groups, especially young children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oxford Vaccine Group
Oxford, Oxfordshire, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.